Understanding these glycosylation patterns is just as important as analyzing other tools like labeled peptides, which are ...

Nipocalimab, a neonatal Fc receptor (FcRn) blocker, is under development for the treatment of multiple IgG autoantibody- or alloantibody-driven diseases.

A comprehensive portfolio of Fc receptor-related products is available to support Fc-mediated binding affinity studies, including: FcγRs, FcRn proteins FcR binding kits (TR-FRET) ...